Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough

  title={Effect of a Novel NOP Receptor Agonist (SCH 225288) on Guinea Pig Irritant-Evoked, Feline Mechanically Induced and Canine Infectious Tracheobronchitis Cough},
  author={Robbie L Mcleod and Deen Bandhu Tulshian and Ginny D. Ho and Xiomara Fernandez and Donald C Bolser and L. Edgar Parra and Jennifer C Zimmer and Christine H Erickson and Ahmad B. Fawzi and Huchappa Jayappa and Craig Lehr and Jason Erskine and April Smith-Torhan and Hongtao Zhang and John A. Hey},
  pages={153 - 161}
Background: Previous studies have demonstrated that nociceptin/orphanin FQ (N/OFQ), the endogenous peptide ligand for the G-protein-coupled NOP receptor, inhibits cough in experimental models. SCH 225288 is a nonpeptide, orally active NOP agonist that may provide the foundation for the development of novel treatments for cough. Methods: First we characterized the selectivity of SCH 225288 in human receptor binding assays. Afterwards, the antitussive activity of SCH 225288 was studied in three… 

Figures and Tables from this paper

Novel Mixed NOP/Opioid Receptor Peptide Agonists
N/OFQ(1-13)-NH2 has been identified as the most potent dual NOP/mu receptor peptide agonist so far described and exerted antitussive effects in an in vivo model of cough.
The Efficacy of a NOP1 Agonist (SCH486757) in Subacute Cough
The effect of NOP1 receptor agonist SCH486757 with matched placebo and codeine in a multicentre, double-blind, parallel-group study in patients with subacute cough showed some hints of possible limited antitussive efficacy.
Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.
  • N. Zaveri
  • Biology, Medicine
    Journal of medicinal chemistry
  • 2016
The progress toward validating the NOP-N/OFQ system as a therapeutic target is discussed, suggesting that NOP agonists may have clinical utility for pain treatment and substance abuse pharmacotherapy.
NOP-Related Mechanisms in Pain and Analgesia.
A considerable number of electrophysiological and anatomical experiments have been conducted in an attempt to explain the complicated profile resulting from NOP receptor modulation, to examine receptor plasticity, and to elucidate mechanisms by which selective NOP agonists, bifunctional NOP/mu agonist, or Nop receptor antagonists modulate acute and chronic pain.
Where Are the New Cough Treatments: A Debriefing of Recent Clinical Proof-of-Concept Trials with the NOP Agonist SCH 486757
The position that an unambiguous and actionable ‘road map’ that clearly delineates the pathway forward for new cough suppressants from basic research to and beyond clinical proof-of-concept studies will be an important aspect for future success of this pharmacological class of drug is supported.
NOP-Targeted Nonpeptide Ligands.
Advances such as G protein-coupled receptor (GPCR) structure elucidation, functional selectivity in ligand-driven GPCR activation, and multi-targeted ligands provide new scope for the rational design of novel NOP ligands fine-tuned for successful clinical translation.
Endogenous opiates and behavior: 2009
Coughing in Small Animal Patients
Current understanding about cough pathophysiology, diagnostic strategies used to uncover underlying etiology of cough, and available options for controlling cough are reviewed, including novel antitussive therapies used in human medicine are examined.


Nociceptin inhibits cough in the guinea‐pig by activation of ORL1 receptors
Findings indicate that selective ORL1 agonists display the potential to inhibit cough by both a central and peripheral mechanism, and potentially represent a novel therapeutic approach for the treatment of cough.
Effect of nociceptin in acid-evoked cough and airway sensory nerve activation in guinea pigs.
The results indicate that the inhibitory effect of nociceptin on acid-induced cough may result from a direct inhibitory effects on peripheral C-fiber activity caused by the selective inhibition of acid- induced transient receptor potential vanilloid-1 activation.
Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung.
Nociceptin-induced inhibition of tachykinergic neurotransmission in guinea pig bronchus.
Data indicate that nociceptin may influence airway physiology by modulating tachykinergic neurotransmission, and is found to be expressed in the upper vagal sensory ganglion, where the cell bodies of the tachyKinin-containing sensory neurons are located.
Nociceptin/orphanin FQ inhibits capsaicin‐induced guinea‐pig airway contraction through an inward‐rectifier potassium channel
Results indicate that N/OFQ‐induced hyperpolarization of tachykinin containing airway sensory nerves, through an inward‐rectifier K+ channel activation, accounts for the inhibition of capsaicin‐evoked broncoconstriction.
Antitussive effect of nociceptin/orphanin FQ in experimental cough models.
Preclinical findings showing that activation of the 'opioid-like' receptor (NOP(1)) inhibits cough in the guinea pig and cat are discussed.
Pharmacology of nociceptin and its receptor: a novel therapeutic target
New advances have contributed to better understanding of the pathophysiological role of the NC/OP4 system, and ultimately will help to identify the therapeutic potential of new OP4 receptor ligands.
Antitussive action of nociceptin in the cat.